Gastrointestinal stromal tumor (GIST) with liver metastases an 18-year experience from the GIST cooperation group in North China

AbstractApproximately 40% to 50% of gastrointestinal stromal tumor (GIST) patients will have recurrence or metastases after resection of the primary lesion, and the most common affected sites will be liver and peritoneum. Imatinib has been considered as the first-line therapy of metastatic GIST. Sur